18. Genetics of breast cancer

International Journal of Clinical Practice

Volumn 56, Issue 9, 2002, Pages 677-682

  Irving, M ^a   Elmslie, F ^a   Berg, J ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; CLINICAL EXAMINATION; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC SCREENING; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LUNG EMBOLISM; MAMMOGRAPHY; MASTECTOMY; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; VAGINA BLEEDING; VAGINA DISCHARGE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MUTATION; PEDIGREE; RISK ASSESSMENT; RISK FACTORS;

EID: 0036856396     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Collaborative Group on Hormonal factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. Lancet 2001; 358: 1389-1398.
2. Data from the Office of National Statistics, UK, 1998.
3. Pharoah PD, Day NE, Duffy S et al. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997; 71: 800-809.
4. Connor F, Bertwistle D, Mee PJ et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet 1997; 17: 423-430.
5. Hall JM, Lee MK, Newman B et al. Linkage analysis of early onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684-1689.
6. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92.
7. Dunning AM, Chiano M, Smith NR et al. Common BRCA1 variants and susceptibility to breast and ovarian cancer. Hum Mol Genet 1997; 6(2): 285-289.
8. Couch FJ, Weber BL, and the Breast Cancer Information Core. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Hum Mut 1996; 8: 8-18.
9. Tonin P, Weber B, Offit K et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nature Med 1996; 2(11): 1179-83.
10. Shattuck-Eidens D, Oliphant A, McClure M et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations: risk factor analysis and implications for genetic testing. JAMA 1997; 278(15): 1242-1250.
11. Abeliovich D, Kaduri L, Lerer I et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997; 60: 505-514.
12. Thorlacius S, Olafsdottir G, Tryggvadottir L et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nature Genet 1996; 13: 117-119.
13. Friedman LS, Gayther SA, Kurosaki T et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997; 60: 313-319.
14. Gayther SA, de Foy KAF, Harrington P, The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators et al. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. Cancer Res 2001; 60: 4513-4518.
15. Peto J, Collins N, Barfoot R et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early onset breast cancer. J Natl Cancer Inst 1999; 91: 904-905.
16. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62(3): 676-689.
17. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet 1997; 60: 496-504.
18. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57: 1457-1462.
19. Ellis D, Greenman J, Hodgson S et al. Low prevalence of germline BRCA1 mutations in early onset breast cancer without a family history. J Med Genet 2000; 37: 792-794.
20. Claus EB, Schilkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77(11): 2318-2324.
21. Malone KE, Daling JR, Neal C et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast cancer cases. Cancer 2000; 88: 1393-1402.
22. Hemminki K, Vaittinen P. Familial breast cancer in the family-cancer database. Int J Cancer 1998; 77: 386-391.
23. Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. JAMA 1993; 270: 1563-1568.
24. Olsen JH, Seersholm N, Boice JD et al. Cancer risk in close relatives of women with early-onset breast cancer: a population-based incidence study. Br J Cancer 1999; 79: 673-679.
25. Ford D, Easton DF, Bishop DT et al, Breast Cancer Linkage Consortium. Risks of cancer in BRCA1 mutation carriers. Lancet 1994; 343: 692-695.
26. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the Cancer and Steroid Hormone Study. Am J Hum Genet 1991; 48: 232-242.
27. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408.
28. Risch HA, McLaughlin JR, Cole DE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68: 700-710.
29. Benichou J, Gail MH, Mulvihill JJ. Graphs to estimate an individualized risk of breast cancer. J Clin Oncol 1996; 14: 103-110.
30. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Cancer 1994; 73: 643-651.
31. Blamey RW. The British Association of Surgical Oncology Guidelines for surgeons in the management of symptomatic breast disease in the UK (1998 revision). BASO Breast Specialty Group. Eur J Surg Oncol 1998; 24: 464-476.
32. Eccles DM, Evans DGR, MacKay J, UK Cancer Family Study Group. Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. J Med Genet 2000; 37: 203-209.
33. Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 2000; 26: 411-414.
34. Ku YL. The value of breast self-examination: meta-analysis of the research literature. Oncol Nurs Forum 2001; 28: 815-822.
35. Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. JAMA 1997; 277: 997-1003.
36. Kerlikowski K, Grady D, Rubin SM et al. Efficacy of screening mammography: a meta-analysis. JAMA 1995; 273: 149-154.
37. Kerlikowski K, Grady D, Barclay J et al. Likelihood ratios for modern screening mammography: risk of breast cancer based on age and mammographic interpretation. JAMA 1996; 276: 39-43.
38. Lalloo F, Boggis CRM, Evans DGR et al. Screening by mammography, women with a family history of breast cancer. Eur J Cancer 1998; 34: 937-940.
39. Warner E, Plewes DB, Shumak RS et al. Comparison of breast magnetic resonance imaging, mammography and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001; 19: 3524-3531.
40. Hartmann LC, Schaid DJ, Woods JE et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77-84.
41. Meijers-Heijboer H, van Geel B, van Putten WLJ et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-164.
42. Fisher B, Constantino JP, Wickerham DL et al. Tamoxifen for prevention for breast cancer: report of the national surgical adjuvant breast and bowel project P-I study. J Natl Cancer Inst 1998; 90: 1371-1388.
43. MacDonald CC, Alexander FA, Whyte BW et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ 1995; 311: 977-980.
44. Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemo-prevention trial. Lancet 1998; 352: 98-101.
45. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93-97.
46. Grodstein F, Stampfer MJ, Colditz GA et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-1775.
47. Stanford JL, Weiss NS, Voigt LF et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 273: 137-142.
48. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: combined reanalysis of data from 51 epidemiological studies involving 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-1059.
49. Collaborative Group on Hormonal Factors and Breast Cancer: Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
50. Ursin G, Henderson BE, Haile RW et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 1997; 57: 3678-3681.
51. Gwinn ML, Lee NC, Rhodes PH et al. Pregnancy, breast feeding and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1990; 43: 559-568.
52. Modan B, Hartge P, Hirsch-Yechezkel G et al, for the National Israel Ovarian Cancer Study Group. Parity, oral contraceptives and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 235-240.
53. Narod SA, Risch H, Mosleshi R et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998; 339: 424-428.
54. Kainu T, Juo SH, Desper R et al. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci USA 2000; 97: 9603-9608.
55. Antoniou AC, Pharoah PD, McMullan G et al. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 2001; 21: 1-18.